ReviewInternational journal of general medicine2026
From Pathophysiological Consensus to Integrative Potential: A Comprehensive Narrative Review of Traditional Chinese Medicine Interventions for Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD) and Future Directions.
Review in International journal of general medicine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Metabolic dysfunction-associated steatotic liver disease (MASLD), previously known as non-alcoholic fatty liver disease, is the most prevalent chronic liver disease globally, with a worldwide prevalence over 30%. Its complex pathogenesis involves insulin resistance, lipid metabolism disorders, mitochondrial dysfunction, gut-liver axis imbalance, chronic inflammation and genetic susceptibility. Currently, no radical pharmacological treatment is clinically approved for MASLD, resulting in a huge unmet clinical demand. Traditional Chinese Medicine (TCM) presents unique strengths in multi-target regulation and long-term prognosis improvement for MASLD, yet fragmented mechanistic evidence and inconsistent syndrome differentiation criteria limit its international application. This narrative review systematically summarizes the latest epidemiological, pathophysiological and diagnostic progress of MASLD, and clarifies the internal correlation between TCM theories and modern pathological mechanisms. Relevant domestic and foreign literature published from 2015 to 2025 was retrieved and analyzed to compare the advantages and limitations of Western medicine and TCM interventions. Western medicine mainly adopts lifestyle intervention, targeted drugs and bariatric surgery, while TCM therapies including herbal formulas, active ingredients, acupuncture and moxibustion improve MASLD through regulating lipid metabolism, stabilizing intestinal microecology, inhibiting inflammation and modulating hepatocyte autophagy, with reliable clinical efficacy. Nevertheless, non-uniform quality standards and insufficient high-level clinical trials restrict the standardized development of TCM. In conclusion, TCM's holistic and multi-target characteristics perfectly adapt to the multifactorial pathogenesis of MASLD. Future studies should combine multi-omics and precision medicine to unify TCM diagnostic and pharmaceutical standards and conduct high-quality multicenter trials, promoting the standardization and international popularization of TCM in MASLD management.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.